



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6:	T	T	(11) International Publication Number: WO 97/00879
С07Н 5/06	A1	1	
		Ľ	43) International Publication Date: 9 January 1997 (09.01.91)
(21) International Application Number: PCT/SI (22) International Filing Date: 20 June 1996 (30) Priority Data: 9502264-6 21 June 1995 (21.06.95) (71) Applicant (for all designated States except US): STITUTE FOR SOCIO-MEDICAL RESEARCH Case postale 718, CH-2001 Neuchâtel (CH). (72) Inventors; and (75) Inventors/Applicants (for US only): DAHLGR [SE/CH]; Chemin des Sauges 14, CH-2015 Are DAHLGREN, Atti-La [SE/CH]; Chemin des S CH-2015 Areuse (CH). KISS, Laszlo [HU/HU]; 32, H-4028 Debrecen (HU). (74) Agents: IVERSEN HASSELROT, Eva et al.; L. A Co. KB, P.O. Box 6107, S-102 32 Stockholm (SI) (54) Title: METHOD FOR PREPARING SULPHATE E FICIENCY VIRUS) INFECTIONS, AND AII (S7) Abstract	E96/008 (20.06.9 ISM, I [CH/Ch LEN, A cause (Ch Lauges 1 Simony Groth E).	SE IN-HI; the ske	(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

Armenia	GB	GB United Kingdom		Malawi
Austria	GE	Georgia	MX	Mexico
Australia .	GN	Guinea	NE	Niger .
Barbados	GR ·	Greece	NL	Netherlands
Belgium	HU	Hungary	NO	Norway
Burkina Faso	IE	Ireland	NZ	New Zealand
Bulgaria	IT	Italy	PL	Poland
Benin	JP	Japan	PT	Portugal
Brazil	KE	•	RO	Romania
Belarus	KG	Kyrgystan	RU	Russian Federation
Canada	KP	Democratic People's Republic	SD	Sudan
Central African Republic		of Korea	SE	Sweden
Congo	KR	Republic of Korea	SG	Singapore
Switzerland	KZ	Kazakhstan	SI	Slovenia
Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
Cameroon	LK	Sri Lanka	SN	Senegal
China	LR	Liberia	SZ	Swaziland
Czechoslovakia	LT	Lithuania	TD	Chad
Czech Republic	LU	Luxembourg	TG	Togo
Germany	LV	Latvia	TI	Tajikistan
Denmark	MC	Морасо	TT	Tripidad and Tobago
Estonia	MD	Republic of Moldova	UA	Ukraine
Spain	MG		UG	Uganda
Pinland	ML	Mali	US	United States of America
France	MN	Mongolia		Uzbekistan
Gabon	MR			Viet Nam
	Austria Australia Barbados Belgium Burkina Faso Bulgaria Benin Brazil Belarus Canada Central African Republic Congo Switzerland Côte d'Ivoire Cameroon China Czechos lovakia Czech Republic Germany Denmark Estonia Spain Finland France	Australia GE Australia GN Barbados GR Belgium HU Burkina Faso IE Bulgaria IT Benin JP Brazil KE Belarus KG Canada KP Central African Republic Congo KR Switzerland KZ Côte d'Ivoire LI Cameroon LK China LR Czechos lovakia LT Czech Republic LU Germany LV Denmark MC Estonia MD Spain MG Finland ML France MN	Australia GE Georgia Australia GN Guinea Barbados GR Greece Belgium HU Hungary Burkina Faso IE Ireland Bulgaria IT Italy Benin JP Japan Brazil KE Kenya Belarus KG Kyrgystan Canada KP Democratic People's Republic Central African Republic of Korea Congo KR Republic of Korea Switzerland KZ Kazakhstan Côte d'Ivoire LI Lichtenstein Cameroon LK Sri Lanka China LR Liberia Czechos kovakia LT Lithuania Czech Republic LU Luxembourg Germany LV Larvia Denmark MC Monaco Estonia MD Republic of Moldova Spain MG Madagascar Finland ML Mali France MN Mongolia	Australia GE Georgia MX Australia GN Guinea NE Barbados GR Greece NL Belgium HU Hungary NO Burkina Faso IE Ireland NZ Bulgaria IT Italy PL Benin JP Japan PT Brazil KE Kenya RO Belarus KG Kyrgystan RU Canada KP Democratic People's Republic SD Central African Republic of Korea SE Congo KR Republic of Korea SG Switzerland KZ Kazakhstan SI Côte d'Ivoire LJ Liechtenstein SK Cameroon LK Sri Lanka SN China LR Liberia SZ Czechos lovakia LT Lithuania TD Czech Republic LU Luxembourg TG Germany LV Latvia TJ Denmark MC Monaco TT Estonia MD Republic of Moldova UA Spain MG Madagascer UG Finland ML Mali US France MN Mongolia

WO 97/00879 PCT/SE96/00824

Method for preparing sulphate esters effective in the treatment of HIV (Human Immuno Deficiency Virus) infections, and AIDS.

The present invention relates to a method for preparing mono-, di-, tri-or tetra-sulphate esters of pentoses and hexoses and their salts, see formulas (I).

5
$$x^5$$
 OR^1
 Y^+
 X^6
 Y^2
 X^6
 X^6
 X^{2+}
 X^{2+}
 X^{2+}
 X^{3}
 X^{2}
 X^{2}
 X^{2}
 X^{2}
 X^{3}
 X^{2}
 X^{2}
 X^{3}
 X^{2}
 X^{3}
 X^{2}
 X^{3}
 X^{3}
 X^{2}
 X^{3}
 X^{3}
 X^{4}
 X^{4}
 X^{5}
 X^{5

Where

R¹ is hydrogen, C₁-C₂-alkyl, benzyl, amino acid,
nucleotide, or polypeptide;

15 R² is OH, SO₄ or NHR³;

R³ is hydrogen, C₁-C₆-alkyl, acetyl or C₂-C₂₄-acyl, aminoacyl or sulphonyl;

X3 is OH or SO4;

X4 is OH or SO,;

20 X5 is OH or SO4;

X' is OH or SO,;

Y', Y'' is H, Na, K, Ca, Zn, Mg, Li, Ba, Mn, Hg, Ag or Au.

Background of the Invention

25 Sulphate esters of hexosamines have been prepared by direct sulphation of hexosamines with chlorosulphonic acid. Previously, Lloyd, A.G. (1962) Biochem. J. 83, 455-460 and Suzuki, S. and Strominger, J.L. (1960) J. Biol. Chem. 235, 267-273 showed that sulphate esters prepared by the direct sulphation of N-acetyllgalactosamine with chlo-30 rosulfonic acid consists of mixtures of mono-and bisulphate esters of the sugar. In a later publication Kazuhiko Ishihara et al. Biochim. Biophys. Acta, 437 (1979) 416-430, synthesised N-acetylgalactosamine-4,6-disulphate. UDP-GalNAc-35 4-sulphate was treated with chlorosulfonic acid, the disulphated nucleotide thus prepared was hydrolysed with 0.01 M HCl to result in N-acetylgalactosamine-4,6-disulphate. In

CONFIRMATION COPY

an other paper Yasuo Nakanishi et al. J. of Biol. Chem. vol. 256 No. 11 (1981) 5443-5449, sulphate was introduced into position 6 of the nonreducing terminal N-acetylgalactosamine-4-sulphate by a terminal 6-sulphotransferase.

5

10

5

10

15

Description of the Invention

The general method for preparing sulphated pentoses and hexoses according to the invention include sulphation with sulphur trioxide-triethylamine complex of hydroxyl-protected sugars in a polar solvent, such as N,N-dimethyl formamide at 20-80°C, preferably 30-70°C, most preferably 40-60°C. This reaction step is very effective and yield almost quantitative yields in mild conditions, it is also very efficient in producing specially designed sulphate esters.

The sulphation method according to the invention also include catalytic hydrogenation in presence of a catalyst, such as palladium hydroxide, to give compounds with

formulas (I).

One embodiment of the present invention is the method for preparation of sulphate ester derivatives of N-acetyl-D-galactosamine. The method comprises treatment of N-acetyl-D-galactosamine with benzyl alcohol and Amberlite® IR 120 to yield benzyl-N-acetyl-D-galactosaminide. The hydroxyl groups of benzyl-N-acetyl-D-galactosaminide was protected and treated with sulphur trioxide-triethylamine complex in N,N-dimethyl formamide at 20-80°C. Depending on which hydroxyl groups were protected the reaction yielded mono-, di- or tri-sulphate substituted benzyl-N-acetyl-D-galactosaminide. The sulphated galactosaminide was catalytically hydrogenated with palladium hydroxide and was commonly worked up to give 50-99% of mono-, di- or tri-sulphate substituted N-acetyl-D-galactosamine.

A further embodiment of the present invention is a method for preparation of sulphate ester derivatives of N-acetyl-D-glucosamine. The preparation procedure followed the same route as described above and yielded after

common workup procedures 50-99% of mono-, di- or trisulphate substituted N-acetyl-D-glucosamine.

The following examples are given by way of example the invention only and not by way of limitation thereof.

Example 1

3,4,6-tri-O-sulpho-N-acetyl-D-galactosamine

A solution of benzyl-N-acetyl-D-galactosaminide 10 (155mg) was stirred in N,N-dimethyl formamide (2 ml) for 15 hours at 50°C in presence of sulphur trioxide-triethylamine complex (380mg). The mixture was cooled and methanol (1 ml) was added. The mixture was chromatographed on a silica gel (30 g) column with ethylacetate:pyridine-15 :acetic acid:water (8:5:1:3) to yield a pure fraction, this was solved in methanol (1 ml) and was further eluated from a Sephadex[®] SP 25 (Na*-form 2x25 cm) column with methanol:water (1:9) to afford the 3,4,6-tri-O-sulphoderivative (220 mg, 80%). The benzyl-groups were removed 20 in a solution of ethanol:water (2:1) and catalytic hydrogenation in presence of palladium hydroxide (20% Pd) for 1 day. The suspension was filtered and concentrated, finally lyophilised. SO calc. 64.86% found 63.5%.

25 <u>Example 2</u>

30

35

3,4-di-sulpho-N-acetyl-D-galactosamine

A solution of benzyl 4,6-O-benzylidene-N-acetyl-D-galactosaminide (1 mmol) and sodium cyanoborhydride (9 mmol) in dry THF (15 ml) containing powdered 3A molecular sieves was cooled to 0°C. Hydrogen chloride in diethyl ether was added dropwise until the solution was acidic (pH paper, gas evolution). The mixture was monitored with TLC and when completed (after 10 min. at 0°C) it was poured into ice-water. The product was extracted with dichloromethane and purified on a silica gel column. The 6-O-benzyl derivative (278mg, 85%) was O-sulphated as described in example 1 to give 3,4-di-sulpho-N-acetyl-D-

galactosamine (75mg, 91%). SO calc. 50.65% found 49.0%.

Example 3

4,6-di-D-sulpho-N-acetyl-D-galactosamine

5 A solution of benzyl-4,6-0-benzylidene-N-acetyl-D-galactosaminide (400 mg) in dry N, N-dimethylformamide (6 ml) was stirred at 0°C in presence of barium oxide (845,5 mg), barium hydroxide 8 H_2O (261 mg) and benzyl bromide (232 μ 1) was added. After completion of the 10 reaction (TLC, dichloromethane:methanol (95:5)) the excess of benzyl bromide was quenched with methanol (150 μ l). The mixture was diluted with chloroform, washed with water, dried (Na,SO4) and concentrated. The residue was crystallized from ethanol yielding 472 mg (70%) of product. The benzylidene group was removed by treatment 15 of the product (400mg) with 60% acetic acid in water (10ml) with stirring at 60 C for 3 hours, then cooled, and concentrated. The acetic acid was removed by repeated evaporation with toluene and 295 mg (90%) of 3-0-benzyl 20 derivative was obtained. This compound was O-sulphated as described in example 1 and gave 74,8 mg (83%) of 4,6-di-O-sulpho-N-acetyl-D-galactosamine. SO calcd. 50.65%, Found 49.5%.

25 Example 4

30

35

4-0-sulpho-N-acetyl-D-galactosamine

A solution of benzyl-4,6-0-benzylidene-N-acetyl-D-galactosaminide (400 mg) was treated as described in example 3. The di-O-benzyl derivative was O-sulphated as described in example 1 to give 4-0-sulpho-N-acetyl-D-galactosamine (180mg, 91%). NMR data: 2,1 ppm s N-Ac; 3,6-4 ppm m skeleton H; 4,1-4,2 ppm m C⁶-H; 4,6 ppm d C⁴-H; 5,2 ppm d anomer H. The NMR spectra were recorded on a Brucker 200 instrument. SO calc. 32.0% found 30.6%.

Example 5

3-sulpho-N-acetyl D-galactosamine

10

15

20

25

30

Benzyl-N-acetyl-D-galactosaminide (400 mg) was treated with benzaldehyde dimethylacetal to give 450 mg (88%) of 4,6-O-benzylidene derivative. O-Sulphation was achieved with the sulphur trioxide-triethylamine complex in N,N-dimethylformamide yielding 431,3 mg (90%) of 3-O-sulpho-derivative from 400 mg of starting material. The product (350 mg) was catalytically hydrogenated in ethanol-water in presence of palladium hydroxide giving 200 mg (91%) of 3-O-sulpho--N-acetyl-galactosamine. SO calcd. 32%, found 30,2%.

Example 6

6-O-sulpho-N-acetyl-D-galactosamine

Benzyl-N-acetyl-D-galactosaminide (300 mg) was stirred with trityl chloride (300 mg) and silver nitrate (250 mg) in pyridine (5 ml) at room temperature for 24 hours. The reaction mixture was partitioned between dichloromethane and water and the organic layer was concentrated. Column chromatography of the residue (dichloromethane-methanol (9:1)) gave 6-0-trityl derivative (373mg, 70%).

The product was benzylated as described earlier to obtain 3,4-di-O-benzyl derivative. To remove the 6-O-trityl group this derivative was treated with trifluoro acetic acid (10 ml 1 % in dichloromethane) at room temperature for 20 hours. Column chromatography of the residue on silica gel gave 3,4-di-O-benzyl-6-OH derivative (284mg, 90%). The 3,4-di-O-benzyl-6-OH derivative was O-sulphated as described in example 1 to give 6-O-sulpho-N-acetyl-D-galactosamine (177mg, 92%). SO calc. 32.0% found 30.3%.

10

30

Claims

A method for preparing mono-, di-, tri-or tetrasulphate esters of pentoses and hexoses, and salts there of, according to formulas (I)

where

15 R1 is hydrogen, C₁-C₆-alkyl, benzyl, amino acid, nucleotide, or polypeptide;

> R^2 is OH, SO, or NHR3;

R3 is hydrogen, C_1-C_6 -alkyl, acetyl or C_2-C_{24} -acyl, aminoacyl or sulphonyl;

20 Χ³ is OH or SO,;

> X4 is OH or SO,;

> Хs is OH or SO4;

> Χe is OH or SO,;

Y+, Y2+ is H, Na, K, Ca, Zn, Mg, Li, Ba, Mn, Hg, Ag or 25


Au,

characterized in that the sulphation step include treatment with sulphur trioxide-triethylamine complex.

- 2. A method according to claim 1, characterized in that the solvent used in the sulphation step is N,Ndimethylformamide.
- 35 A method according to claim 1 or 2, characterized in that the reaction temperature of the sulphation step is in the range from 20 to 80°C, preferably from 30

to 70°C, most preferably from 40 to 60°C.

- 4. A method according to any of the claims 1-3, characterized in that the method comprises a catalytic hydrogenation step.
- 5. A method according to claim 4, characterized in that the catalyst is palladium hydroxide.
- 10 6. A method according to claim 5, characterized in that method comprises a protection step, wherein hydroxyl groups of the sugar is protected before the sulphation step.
- 7. A method according to any of the claims 1-6, characterized in that the pentoses and hexoses are selected from the group consisting of ribose, xylose, arabinose, galactose, glucose or mannose.
- 20 8. A method according to any of the claims 1-7, characterized in that the pentoses and hexoses have an amine-group in position 2.
- 9. A method according to claim 8, characterized in that the prepared hexosamine is a mono-, di-or trisulphate substituted N-acetyl-D-galactosamine derivative.
 - 10. A method according to claim 8, characterized in that the prepared hexosamine is a mono-, di-or tri-
- 30 sulphate substituted N-acetyl-D-glucosamine derivative.
 - 11. A method according to claim 8, characterized in that the prepared pentosamine is a mono-or di-sulphate substituted N-acetyl-D-ribosamine derivative.



International application No.


PCT/SE 96/00824 A. CLASSIFICATION OF SUBJECT MATTER IPC6: C07H 5/06 According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC6: C07C, C07H Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched SE,DK,FI,NO classes as above Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) WPI, IFIPAT, CA C. DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. Carbohydr. Chem., Volume 7, No 3, 1988, I.G. Leder, X,Y 1-11 "Synthesis of the 3-0, 4-0 and 6-0 Sulfates of Methyl 2-Amino-2-deoxy-alpha-D-glucopyranoside" page 583 - page 592 Carbohydr. Res., Volume 93, 1981, P.J. Archbald et al, "13C-NMR Studies of D-glucose and D-galactose Monosulphates" page 177 - page 190 X,Y 1-11 Y US 4992533 A (RIKAGAKU KENKYUSHO, MECT CORP.), 1-11 12 February 1991 (12.02.91) X Further documents are listed in the continuation of Box C. See patent family annex. Special categories of cited documents: later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "A" document defining the general state of the art which is not considered to be of particular relevance erlier document but published on or after the international filing date "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "O" document referring to an oral disclosure, use, exhibition or other document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report 27 Sept 1996 01-10-1996 Name and mailing address of the ISA/ Authorized officer Swedish Patent Office Box 5055, S-102 42 STOCKHOLM


Form PCT/ISA/210 (second sheet) (July 1992)

Facsimile No. +46 8 666 02 86

Teddy Ercegovic

Telephone No. +46 8 782 25 00





		/SE 96/00824
	ation). DOCUMENTS CONSIDERED TO BE RELEVANT	
Category*	Citation of document, with indication, where appropriate, of the relevant p	passages Relevant to claim N
r	US 5385891 A (TANABE SEIYAKU CO., LTD), 31 January 1995 (31.01.95)	1-11
	US 5116821 A (THE PROCTER & GAMBLE COMPANY), 26 May 1992 (26.05.92)	1-11
	•	
	,	
	·	
	·	· «
	·	
	•	
	·	
	10 (continuation of second sheet) (July 1992)	·



Information on patent family members

05/09/96

International application No.

PCT/SE 96/00824

	document earch report	Publication date	Patent family member(s)		Publication date 23/05/91 05/04/90 12/04/94 04/04/90 09/04/90
JS-A-	4992533	12/02/91	AU-B- 610760 AU-A- 4231689 CA-A- 1328450 EP-A- 0361490 JP-A- 2096588		
IS-A-	5385891	31/01/95	CA-A- EP-A- JP-A-	2075850 0531016 5112601	01/03/93 10/03/93 07/05/93
JS-A-	5116821	26/05/92	NONE		

Form PCT/ISA/210 (patent family annex) (July 1992)